Join our community of smart investors

Bull vs. Bear: GlaxoSmithKline

In the latest instalment of Bull vs Bear, Megan Boxall takes on Simon Gergel from The Merchant’s Trust to argue the investment case of Britain’s biggest pharma company
May 16, 2018

GlaxoSmithKline (GSK) is a company which divides opinion and therefore an ideal candidate for the ICs Bull vs Bear series. In this episode, Simon Gergel from the Merchants Trust argues the bull case against the ICs pharma specialist (and GSK sceptic), Megan Boxall.

Produced by Graeme Davies